Erasca, Inc.

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS and the MAPK pathway account for more than five million new patients diagnosed with cancer globally each year. The company was co-founded by pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to shut down the RAS/MAPK pathway. Erasca's RAS/MAPK pathway pipeline includes modality-agnostic programs aligned with three therapeutic strategies: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. This approach allows for a systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches aimed at prolonging survival in patient populations with high unmet medical needs. The modality-agnostic approach enables selective and potent targeting of critical signaling nodes with the most appropriate modality, including small and large molecule therapeutics. The pipeline includes two clinical-stage programs: ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor. It also includes ERAS-12, a discovery-stage program (an EGFR D2/D3 biparatopic antibody), for which a lead candidate has been identified.